The Oncology Institute, Inc.
HealthcareNASDAQ:TOI · NASDAQ Capital Market
+$0.18 today
Vol 1.25M · Avg 1.94M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
385.5%
avg -204.1%
ROIC
-35.7%
avg -14.6%
ROA
-36.8%
avg -18.5%
Analysis
ROE is currently the strongest return metric at 385.5% versus its period average of -204.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel Virnich FACHE | Chief Executive Officer & Executive Director | $699,929.00 | — | 47 | $2.34M | 2.34% |
Yale D. Podnos | Chief Medical Officer | $596,825.00 | — | 54 | $259,527.00 | 0.26% |
Robert Carter | Chief Financial Officer | $509,130.00 | — | 40 | $414,801.00 | 0.41% |
Rakesh Panda | Chief Information Officer | — | — | — | — | — |
Nolan Mariano | Chief People Officer | — | — | — | — | — |
Austin Lee | Vice President of Accounting & Controller | — | — | — | — | — |
Minh Merchant | Chief Legal Officer | — | — | 53 | — | — |
Jordan McInerney | Chief Development Officer | — | — | — | — | — |
Kristin England | Chief Administrative Officer | — | — | — | $0.00 | <0.01% |
Stephen Cella | Senior Vice President of Finance | — | — | — | — | — |
Mark Hueppelsheuser | General Counsel | — | — | — | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$2.33M
Sells
11
$21.50M
Net Sentiment
$19.16M
Net selling
Most Active
Chernett Jorey
12 transactions
1–10 of 23
Analysis
Insiders reported 12 buys worth $2.33M and 11 sells worth $21.50M over the last 12 months. That adds up to net selling of $19.16M. Chernett Jorey was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +17.6% | +27.6% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | +138.2% (6yr)1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +17.6% over three years. Forward estimates point to Net Income at +138.2% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Agilon Health, Inc.
NYSE:AGL
$1.88B
Enhabit, Inc.
EHAB
$706.91M
Sonida Senior Living, Inc.
NYSE:SNDA
$700.96M
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
OrthoPediatrics Corp.
NASDAQ:KIDS
$457.71M
Evolus, Inc.
NASDAQ:EOLS
$443.20M
Cross Country Healthcare, Inc.
NASDAQ:CCRN
$434.69M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Auna S.A.
NYSE:AUNA
$364.93M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.38M
Who manages TOI?
The Oncology Institute, Inc. (TOI) lists 11 active executives. The top listed executive is Rakesh Panda, Chief Information Officer.
Are TOI insiders buying or selling?
Recent insider activity shows net selling of $23.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.